Biomarin Pharmaceutical Inc at Cowen Health Care Conference Transcript
(technical difficulty)
give presentation in this room. It'll be probably partial amount of the time, we'll also do a bit of a fireside chat when J.J. is done with his prepared remarks. In the back, we also have CFO, Dan Spiegelman; and Traci McCarty of Investor Relations. J.J.?
©,-&
Thank you, Phil. Good morning, everybody. Pleasure to be here. This presentation will contain forward-looking statements, so please refer to our SEC filings.
So BioMarin is a 21-year old company. We now have 7 approved products in the market. We anticipate that they will be generating around $2 billion of revenue next year. And we -- in addition to the products on the market, we have a significant pipeline of products: vosoritide for achondroplasia; valrox for hemophilia A gene therapy; tralesinidase alfa for MPS IIIB. We anticipate filing an IND for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
